Breast cancer clinicopathological presentation, gravity and challenges in Eritrea, East Africa: Management practice in a resource-poor setting by Tesfamariam, Asmerom et al.
RESEARCH
526  August 2013, Vol. 103, No. 8  SAMJ
Breast cancer clinicopathological presentation, 
gravity and challenges in Eritrea, East Africa: 
Management practice in a resource-poor setting
A Tesfamariam,1 MD; A Gebremichael,1 PhD; J Mufunda,2 PhD
1  Orotta School of Medicine and Dentistry, Asmara, Eritrea 
2  World Health Organization, Lesotho 
Corresponding author: A Tesfamariam (asmeromp@gmail.com)
Background. In Africa, breast cancer closely compares with cervical cancer as the most common malignancy affecting women and the 
incidence rates appear to be rising. Early detection of breast cancer is a key strategy for a good treatment outcome. However, there is no 
established protocol or guideline for management of breast cancer in Eritrea, East Africa.
Objective. To assess the clinicopathological presentation, gravity and management challenges presented in breast cancer treatment in Eritrea.
Methods. Our investigation was a retrospective, descriptive study to assess the clinical features and severity of breast cancer at time of presentation. We 
reviewed the medical records of all patients who presented with breast malignancies over the 2-year period from 1 January 2007 to 31 December 2008. 
Results. Eighty-two patients ranging in age from 26 - 80 years (mean 48 years) were included in the study. Of these 51% were premenopausal 
women; 61% of the patients presented with breast mass only and the remainder with manifestations of local (mass plus discharge, breast 
pain or breast ulceration) or distant metastatic disease. More than 60% of the patients presented after >2 years following onset of symptoms. 
Two-thirds of patients had late stage (III or IV) disease. All except one case was managed surgically. 
Conclusion. Most cases presented at younger age and advanced stage. These findings call for strengthening health education to promote early 
health-seeking behaviour and advocacy for the introduction of national screening, implementation of a management protocol and establishment 
of a radio-chemotherapy centre. 
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The reported incidence of 
breast cancer in sub-Saharan 
Africa is lower at 20 cases 
per 100 000 population, than 
90/100  000 in the West. [1] 
In Africa, breast cancer closely compares 
with cervical cancer as the most common 
malignancy affecting women and the incidence 
rates appear to be rising.[2] In Nigeria, for 
example, the incidence rate increased from 
13.8 - 15.3/100 000 in the 1980s to 33.6/100 000 
in 1992 and 116/100 000 in 2001.[3]
While mortality rates are declining in the 
developed world because of early diagnosis, 
screening and improved cancer treatment 
programmes, the converse is true in the 
developing world and in eastern and central 
Europe.[1,4]
There is a marked difference in distribution, 
presentation and outcome between developed 
and developing countries. [2,4] In the USA, 
the percentage of patients presenting with 
stage I disease increased from 42.5% (1985) to 
56.2% (1995), while the percentage of patients 
presenting with stage III or stage IV decreased 
from 18.3% to 11.6% during the same time 
period.[5] In contrast, studies of women 
with breast cancer from Tunisia,[6] Sudan,[7] 
Nigeria[8] and South Africa[9] have shown that 
most patients present with advanced stages 
(III and IV) at first healthcare consultation. 
The geographic disparities in incidence rates 
can be attributed mainly to disease-reporting 
patterns and disease awareness. 
About 70 - 90% of breast cancers present 
with breast masses and rarely with nipple 
discharge and pain.[10] Triple Assessment – 
clinical examination, imaging, cytology or 
tissue pathology of a biopsy specimen – 
establishes the diagnosis for most women 
with suspected breast cancer.[11,12]
The prognosis, choice of treatment and 
outcome depend on accurate morphologic 
diagnosis, staging, histologic grade, hor-
mone receptor status and identification of 
biomarkers. The latter two investigations are 
rarely possible in resource-poor countries. 
Treatment of early breast cancer is, however, 
less resource-intensive than advanced breast 
cancer with superior outcomes, the 5-year 
breast cancer survival rate ranges from 98% 
for stage I cancer to approximately 16% for 
stage IV cancer.[13]
According to previous studies undertaken 
in Eritrea, breast cancer is common in young 
women and there is regional variation.[14,15] 
Information regarding clinicopathological 
presentation, gravity and the diagnostic and 
treatment approach is limited and has not 
been well documented. Moreover, there 
is no established protocol/guideline for 
management of breast cancer in Eritrea.
Objective
To assess (i) the clinicopathological presen-
tation, (ii) severity of breast cancer at presen-
tation, (iii) the methods followed in establishing 
the diagnosis, and (iv) the subsequent 
management of patients at 3 referral hospitals 
in Eritrea, East Africa.
Methods
Study design
Our investigation was a retrospective, 
descriptive study of breast cancer in patients 
who attended the General Surgical Units 
of 3  hospitals – Orotta Medical Surgical 
National Referral Hospital, Halibet Hospital 
and Sembel Hospital – from 1 January 2007 
to 31  December 2008. These hospitals serve 
more than three-quarters of the Eritrean 
population requiring surgical interventions.
Study population and data collection 
We reviewed 90 medical records over the 
2-year period, of which we excluded 8 samples 
where data (age, sex, duration of symptoms, 
radiological, pathology, and operative reports 
and treatment received) were incomplete. 
Demographic details, clinical presentation 
and duration of symptoms at initial diagnosis, 
radiological data, cytological and histological 
findings, treatment and postoperative data of all 
patients were entered into our study protocol. 
Checklists for appropriate management, accor-
ding to the recommended guideline for low-
income countries,[16] were prepared during 
data collection. The WHO Tumour, Node and 
Metastasis (TNM) tumour classification and 
cancer staging system was used in this study.[17] 
We performed descriptive data analysis using 
SPSS software (version 14). 
Results
Of the 82 patients in our study, women 
constituted 94% (female:male ratio 15:1.). The 
age range was 26 - 80 years (mean 48.46 years; 
standard deviation (SD) 16.2), the majority of 
patients were ≤55 years with 10% >75 years. 
Seventy-eight (95%) patients were married 
and 4 (5%) were single. Geographically, 51 
(62.2%) patients were from the Central Zone, 
17 (20.7%) from the South zone, 5 (6.1%) 
from the Gash-Barka region, 4 (4.9%) from 
the Southern Red Sea zone and the remaining 
3.7% and 2.4% from the Northern Red Sea and 
Anseba zones, respectively.
The majority of patients presented with 
breast mass only (61%), followed by breast 
mass plus discharge, pain or ulceration (36.6%) 
and the remainder with breast pain only (2.4%) 
with a left-side predominance of disease (56%). 
The duration from onset of symptoms to first 
presentation ranged from 3 months to 10 years 
(mean 2.9 years; SEM 0.27) (Table 1). 
Radiologic imaging (mammography/
ultrasonography or both) was undertaken 
with only 29% of patients; 73% underwent 
cytological examination of their breast masses 
prior to histological diagnosis. One-third of 
patients had resorted to traditional medicine 
as their first choice of treatment. Infiltrative 
ductal carcinoma accounted for 82% of all 
cancers. Invasive lobular carcinoma, papillary 
carcinoma and recurrence each accounted 
for 1.2%. Cribriform, medullary carcinoma 
and phyllodes with other non-specified 
malignancies accounted for 2.4%, 4.0% and 
8.3%; respectively. More than two-thirds of the 
cases were of advanced stage (III and IV, 46% 
and 18%; respectively) (Table 1).
Three-quarters of patients had positive 
lymph node involvement and 18% had distant 
organ metastasis, chiefly to the lungs and 
liver, with associated symptoms of cough and 
jaundice, respectively (Table 2).
The hormone receptor status and biomarker 
profile had not been established in any cases. 
Treatment modalities ranged from excisional 
lumpectomy to palliative wound clearance: 
excisional lumpectomy (n=5; 6.1%) (the 
tumour-free margin could not be defined intra-
operatively in all these cases), modified radical 
mastectomy (MRM) (n=34; 41.5%), radical 
mastectomy (n=6; 7.3%), radical mastectomy 
with axillary lymph node dissection (n=26; 
31.7%) and wound debridement (n=9; 11%). 
Only 1 patient had MRM and chemotherapy. 
One patient refused mastectomy. 
Of 7 patients with stage I disease, 4 
underwent excisional lumpectomy, 2 had 
Table 1. Cancer stage distribution v. duration of symptoms at first presentation
Duration of symptoms (months), n Total
N (%)Stage 3 - 12 13 - 48 49 - 84 75 - 240 
I 4 2 0 1 7 (9)
II 14 7 1 0 22 (27)
III 11 18 9 0 38 (46)
IV 1 3 6 5 15 (18)
Total, N 30 30 16 6 82
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MRM and 1 refused surgical intervention. Of 
22 patients with stage II disease, 18 underwent 
MRM, 3 radical mastectomy and 1 MRM 
with axillary lymph node dissection. Stage IV 
cancer patients received palliative intervention 
and only 6/15 underwent radical mastectomy 
with axillary lymph node dissection.
Discussion
In Eritrea and other East African countries, 
cancer is a neglected disease. Information 
on cancer is limited by the lack of a cancer 
registry and local evidence-based research. 
In our study, 83% of the cases were from 
the highlands (the Central and South zones), 
which are densely populated and where there 
is better access to healthcare facilities and 
better health-seeking behaviour than the 
lowlands. This geographic disparity between 
the highlands and lowlands and between 
urban and rural populaces is consistent 
with the literature, which has documented 
reasons for these disparities. [1,4,8] Our study 
cannot completely reflect the incidence and 
prevalence of breast cancer in Eritrea because it 
was carried out at tertiary hospitals that attend 
to only 75% of the population.
In developed countries, breast cancer is a 
disease of older women. More than 50% of 
patients in our study were premenopausal, 
similar to reports from Nigeria and other 
developing countries.[4,7,8,15] The incidence of 
breast cancer typically increases with age and 
it is rare in patients <25 years old. In the white 
population the incidence is <0.5% in patients 
<35 years old.[4] In our study 26.8% of cases 
were <35 years old. Thus, our results indicate 
that in Eritrea breast cancer is a disease of 
younger, mainly premenopausal women. 
In developing and resource-poor countries 
women with breast cancer present very late 
in the course of the disease,[7,8,18] despite 
symptoms being easily identifiable during 
routine self-examination. 
In our study >70% of patients sought 
consultation >1 year after noticing symptoms 
and presented with advanced stage disease; 
97% presented with breast mass with or 
without additional symptoms such as pain, 
discharge and ulceration. 
The proportion of patients resorting to 
traditional therapy (e.g. herbal, holy water, 
soil) indicated that women in our society 
have poor attitudes towards western medicine, 
further exacerbating the poor outcome and 
prognosis of the disease. None presented with 
ductal carcinoma in situ, with 91% having 
infiltrating/invasive ductal carcinomas with a 
variety of subhistological types consistent with 
the literature from developing countries[4,6-8,17,18] 
where invasive ductal carcinoma is reported in 
70 - 85% of cases.[17]
Consistent with a study from Nigeria,[8] 
18% of patients had distant organ metastasis 
to the liver, lung, vertebrae and brain.
Breast cancer is a heterogeneous disease. 
Treatment outcomes depend on early and 
accurate diagnosis, the pathology of the 
disease, and the availability of adequate 
resources. While Triple Assessment is 
the gold standard for evaluation of breast 
cancer and has a specificity of diagnosis 
approaching 100%,[11,12] this was undertaken 
in only 24% of our cases. Hormone receptor 
analysis is not available in Eritrea.
The only treatment available in our setting 
is surgery, which in our patients ranged from 
excisional lumpectomy to radical mastectomy 
with axillary lymph node dissection. While 
surgery in combination with radiation 
therapy is the management of choice for 
early breast malignancies, and hormonal 
therapy and chemotherapy are administered 
to advanced cases where systemic metastasis 
is presumed,[16] this is not established in 
Eritrea. An additional challenge is the lack of 
frozen-section procedure for the assessment 
of tumour-free margins, with the result that 
breast conservation therapy is hardly possible. 
Without the right techniques to identify 
cancer-free margins, the risk of recurrence 
cannot be minimised. Furthermore, a radio-
chemotherapy centre for cancer has yet to be 
established in Eritrea.
Conclusions
Our study, using retrospective and hospital-
based data, shows that breast cancer patients 
presented at a younger age, with advanced 
disease. 
Limitations of the study
This retrospective case series based on hospital 
data from medical records of patients had 
a relatively small sample size and the true 
distribution of the disease in the country might 
not, therefore, be reflected. 
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Table 2. Distribution of patients with distant organ/system metastasis and grave signs (N=82)
Cases, n Clinical presentation
Distant organ/system metastasis
Vertebral bone 1 Breast mass and back pain
Vertebral bone and brain 1 Breast mass, back pain and hemiplegia
Vertebral bone and liver 1 Breast mass, back pain and jaundice
Liver 4 Breast mass and jaundice
Liver and lung 2 Breast mass, jaundice and cough 
Lung 6 Breast mass and cough
No distant metastasis 67 Breast mass, pain and discharge
